RxDoctor Payments Data

Veena Basava, MD

Pain Medicine · Sugar Land, TXNPI 1700195138

Payments from drug & device makers

$3,916in general payments, 2019–2025

Across 91 payments — averaging $43.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinal Simplicity, LLC$2K
  • Medtronic$1K
  • Abbott$413
  • Collegium Pharmaceutical, Inc.$161
  • Si-bone, Inc.$93
  • Pfizer$77
  • plus $459 from 15 others

What the payments were for

  • Food & beverage$2,39761%
  • Education$1,51939%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,916 in reported general payments places this provider in the 55th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$347,018
Medicare patients
345
Services billed
7,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl44$18,475
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen763$14,049
Xtampza ErOxycodone Myristate24$10,828
NucyntaTapentadol Hcl14$7,355
Naloxone Hcl87$5,321
MovantikNaloxegol Oxalate11$5,260
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen134$4,633
Pregabalin166$4,215
Gabapentin293$2,858
Lidocaine30$2,540
Acetaminophen-CodeineAcetaminophen With Codeine153$2,074
Tramadol Hcl286$1,312
Methocarbamol100$1,132
Tizanidine Hcl93$1,096
Tramadol Hcl ErTramadol Hcl22$1,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$161$36,65782 claims
Redhill Biopharma Inc.Movantik$38$5,26011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →